Chitinase 3 like 1 is a regulator of smooth muscle cell physiology and atherosclerotic lesion stability

Pavlos Tsantilas,Shen Lao,Zhiyuan Wu,Anne Eberhard,Greg Winski,Monika Vaerst,Vivek Nanda,Ying Wang,Yoko Kojima,Jianqin Ye,Alyssa Flores,Kai-Uwe Jarr,Jaroslav Pelisek,Hans-Henning Eckstein,Ljubica Matic,Ulf Hedin,Philip S Tsao,Valentina Paloschi,Lars Maegdefessel,Nicholas J Leeper

DOI: https://doi.org/10.1093/cvr/cvab014

IF: 13.081

2021-02-07

Cardiovascular Research

Abstract:Abstract Aims Atherosclerotic cerebrovascular disease underlies the majority of ischaemic strokes and is a major cause of death and disability. While plaque burden is a predictor of adverse outcomes, plaque vulnerability is increasingly recognized as a driver of lesion rupture and risk for clinical events. Defining the molecular regulators of carotid instability could inform the development of new biomarkers and/or translational targets for at-risk individuals. Methods and results Using two independent human endarterectomy biobanks, we found that the understudied glycoprotein, chitinase 3 like 1 (CHI3L1), is up-regulated in patients with carotid disease compared to healthy controls. Further, CHI3L1 levels were found to stratify individuals based on symptomatology and histopathological evidence of an unstable fibrous cap. Gain- and loss-of-function studies in cultured human carotid artery smooth muscle cells (SMCs) showed that CHI3L1 prevents a number of maladaptive changes in that cell type, including phenotype switching towards a synthetic and hyperproliferative state. Using two murine models of carotid remodelling and lesion vulnerability, we found that knockdown of Chil1 resulted in larger neointimal lesions comprised by de-differentiated SMCs that failed to invest within and stabilize the fibrous cap. Exploratory mechanistic studies identified alterations in potential downstream regulatory genes, including large tumour suppressor kinase 2 (LATS2), which mediates macrophage marker and inflammatory cytokine expression on SMCs, and may explain how CHI3L1 modulates cellular plasticity. Conclusion CHI3L1 is up-regulated in humans with carotid artery disease and appears to be a strong mediator of plaque vulnerability. Mechanistic studies suggest this change may be a context-dependent adaptive response meant to maintain vascular SMCs in a differentiated state and to prevent rupture of the fibrous cap. Part of this effect may be mediated through downstream suppression of LATS2. Future studies should determine how these changes occur at the molecular level, and whether this gene can be targeted as a novel translational therapy for subjects at risk of stroke.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of chitinase - 3 - like protein 1 (CHI3L1) in carotid artery disease and its impact on plaque stability. Specifically, the study aims to:

1. **Determine the expression level of CHI3L1 in patients with carotid artery disease**: By analyzing two independent human endarterectomy biobanks, the study found that the expression of CHI3L1 was significantly up - regulated in patients with carotid artery disease compared to the healthy control group.

2. **Evaluate the relationship between CHI3L1 and symptoms and pathological features**: The study further found that the level of CHI3L1 can stratify individuals according to symptomatology and histopathological evidence of fibrous cap instability.

3. **Explore the function of CHI3L1 in vascular smooth muscle cells (SMCs)**: Through gain - and - loss - of - function experiments in human carotid artery smooth muscle cells cultured in vitro, the study showed that CHI3L1 can prevent these cells from undergoing adverse changes, such as the transition of the phenotype to a synthetic and highly proliferative state.

4. **Verify the role of CHI3L1 in mouse models**: Using two mouse models (carotid artery remodeling model and lesion vulnerability model), the study found that knockdown of Chil1 led to larger neointimal lesions, which were composed of dedifferentiated SMCs and could not be stabilized within the fibrous cap.

5. **Explore the downstream mechanisms of CHI3L1**: Preliminary mechanistic studies suggest that CHI3L1 may affect cell plasticity by regulating potential downstream genes (such as large tumor suppressor kinase 2, LATS2), and LATS2 mediates the expression of macrophage markers and inflammatory cytokines on SMCs.

In summary, this study aims to reveal the mechanism of action of CHI3L1 in carotid artery disease, especially how it affects plaque stability, thereby providing a theoretical basis for the development of new biomarkers or therapeutic targets.